B cell depletion in early rheumatoid arthritis: A new concept in therapeutics

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 729-735

  Renato, Guzman M ^a  

^a Saludcoop Clinic   (Colombia)

Author keywords

B cell depletion; Biological therapy; Rituximab

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHYLPREDNISOLONE; PARACETAMOL; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADULT; B LYMPHOCYTE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT SWELLING; LYMPHOCYTE DEPLETION; MALE; MYALGIA; RESPIRATORY TRACT INFECTION; RETREATMENT; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SHIVERING;

EID: 69949121674     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04626.x     Document Type: Conference Paper

References (45)

1. Choy, E.H. & Gs. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344: 907-916.
2. Bingham, C.O. 2008. Emerging therapeutic for rheumatoid Arthritis. Bull. NYU Hosp. Jt. Dis. 66: 210-215.
3. Guzman, R.A. 2003. Artritis feumatoidea: bases in-munológicas para la terapia biológica. Rev. Colomb. Reumatol. 10: 11-35.
4. Olsen, N.J. & C.M. Stein. 2004. New drugs for rheumatoid arthritis. N. Engl. J. Med. 350: 2167-2179.
5. O'Dell, J.R. 2004. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. 350: 2591-602.
6. Stanczyk, J., C. Ospelt & S. Gay. 2008. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr. Opin. Rheumatol. 20: 257-22.
7. Goekoop-Ruiterman, Y.P.M., J.K. de Vries-Bouwstra, C.F. Allaart, et al. 2007. Comparison of treatment strategies in early rheumatoid arthritis. Ann. Intern. Med. 146: 406-415.
8. O'Dell, J.R. 2007. It is the best of times: it is the worst of time: is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues. Arthritis Rheum. 56: 3884-3886.
9. Kremer, J.M., H.K. Genant, L.W. Moreland, et al. 2006. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144: 865-876.
10. Ohsugi, Y. & T. Kishimoto. 2008. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 8: 669-681.
11. Park, J.Y. & M.H. Pillinger. 2007. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull. NY Hosp. Jt. Dis. 65(Suppl 1): s4-10.
12. Edwards, J.C.W., L. Szczepanski, J. Szechinski, et al. 2004. Efficacy of B-cell targeted therapy with ritux-imab in patients with rheumatoid arthritis. N. Engl. J. Med. 350: 2572-2581. (Pubitemid 38758544)
13. Tsokos, G.C. 2004. B cells, be gone. B cell depletion in the treatment of rheumatoid arthritis. N. Engl. J. Med. 350: 2546-2548.
14. Silverman, G.J. & D.G. Carson. 2003. Roles of B cells in rheumatoid arthritis. Arthritis Res. Ther. 5(9 suppl 4): s1-6.
15. Cohen, S.B. 2006. Updates from B cell trial: efficacy. J. Rheumatol. 33: 12-17.
16. Dorner, T. & G.R. Burmester. 2008. New approaches of B-cell-directed therapy: beyond rituximab. Curr. Opin. Rheumatol. 20: 263-268.
17. Dorner T. & G.R. Burmester. 2003. The role of B cells in rheumatoid arthritis: mechanism and therapeutic targets. Curr. Opin. Rheumatol. 15: 246-252.
18. Edwards, J.C., G. Cambridge & V.M. Abrahams. 1999. Do self-perpetuating B lymphocytes drive human auto immune's disease? Immunology 97: 188-196.
19. Saag, K.G., G.G. Teng, N.M. Patkar, et al. 2008. American College of Rheumatology Recommendations for the use of no biologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59: 762-784.
20. Bathon, J.M. & S.B. Cohen. 2008. The 2008 American College of Rheumatology Recommendations for the use of no biologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: Where the rubber meets the road. Arthritis Rheum. 59: 757-759.
21. McGonagle, D., A.L. Tan, J. Madden, et al. 2008. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology, April 4; 1-3.
22. Arnett, Fc., S.M. Edworthy, D.A. Bloch, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324.
23. Panay, G.S. 2005. B cells: a fundamental role in the pathogenesis of Rheumatoid Arthritis? Rheumatology 44(suppl 2): ii3-7.
24. Teitelbaum, S.L. 2008. Osteoclast: What do they do and how do they do it? Am. J. Pathos. 170: 427-435.
25. Thomas, R., M. Turner & A.P. Cope. 2008. High avidity autoreactive T cells with a low signaling capacity through the T-cell receptor: central to Rheumatoid Arthritis pathogenesis? Arthritis Res. Ther. 10: 210.
26. Protheroe, A., J.C. Edwards, A. Simmons, et al. 1999. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-hodking's lym-phoma. Rheumatology 38: 1150-1152.
27. Kastbom, A., G. Stranberg, A. Lindroos, et al. 2004. Anti-CCP antibody test predicts the disease course during three yeas in early rheumatoid arthritis. Ann. Rheum. Dis. 63: 1085-1089.
28. Arbuckle, M.R., M.T. McClain, M.W. Rubertone, et al. 2003. Development of auto antibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349: 1526-1533.
29. Shmerling, R.H. 2003. Auto antibodies in Systemic lupus erythematosus. There before you know it. N. Engl. J. Med. 349: 1499-1500.
30. De Vita, S., F. Zaja, S. Sacco, et al. 2002. Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenic role of B cells. Arthritis Rheum. 46: 2029-2033.
31. Keystone, E., R. Fleischmann, P. Emery, et al. 2007. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis. Arthritis Rheum. 56: 3896-3908.
32. Cohen, S.B., P. Emery, M. Greenwald, et al. 2006. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 54: 2793-2806.
33. Jois, R.N., A. Masding, M. Somerville, et al. 2007. Rit-uximab therapy in patients with resistant rheumatoid arthritis: real-life experience. Rheumatology 46: 980-992.
34. Deighton, C. & K. Hyrich. 2008. International guidelines on access to biologic therapy: Why the differences and which is best? Nat. Clin. Pract. Rheumatol. 4: 520-521.
35. Emery, P., W.F. Rigby, B. Combe, et al. 2008. Efficacy and safety of rituximab as first-line biologic therapy in patients with active rheumatoid arthritis; Results of a phase III randomized controlled study.(SERENE). Arthritis Rheum. 58(suppl 9): s302-364.
36. Deodhar, A., J. Isaacs, W. Rigby, et al. 2008. Improved quality of life with rituximab as first-line biological therapy of patients with active rheumatoid arthritis: Results of a phase III randomized controlled study. (SERENE). Arthritis Rheum. 58(suppl 9): s302-365.
37. Emery, P., R. Fleishmann, A. Filipowicz-Sosnowska, et al. 2006. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum. 54: 1390-1400.
38. Guzman, R.A., et al. 2008. B cell depletion in poly-dermatomyositis. 6th International Congress on Autoimmunity. Porto, Portugal. Abstracts www.kenes.com/autoimmunity.
39. Guzman, R.A., M.V. Mera, O. Garcia, et al. 2008. New treatment in lupus nephritis: Combined therapy with rituximab and mycophenolate mofetil. Ann. Rheum. Dis. 67(suppl II). Abstract; 219: THUO260.
40. Guzman, R.A., G.M. Roa, D. Prada. 2005. Ritux-imab in refractory systemic lupus erythematosus. Lupus 14: 221; OP18.
41. Guzman, R.A., G. Roa & W. Otero. 2006. Rituximab in primary sjogren syndrome. J. Clin. Rheumatol. 12: s52; 164.
42. Hauser, S.L., E. Waubant, D.L. Arnold, et al. 2008. B-cell depletion with rituximab in relapsing-remitting multiple Sclerosis. N. Engl. J. Med. 358: 676-688.
43. McFarland, H.F. 2008. Focus on research: The B cell. Old player, new position on the team. N. Engl. J. Med. 358: 664-666.
44. Gunnarsson, I., B. Sundelin, T. Jonsdottir, et al. 2007. Histophatologic and clinical outcome of ritux-imab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56: 1263-1272.
45. Aletaha, D., R. Landewe, T. Karonitsch, et al. 2008. Reporting disease activity in clinical trials of patient with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum. 59: 1371-1377.